• Home
  • Contact us
雀盔肺弊牢 ID PW Forgot ID/PW Register Automatically Log me on

New antiplatelet drugs and novel oral anticoagulant during percutaneous coronary intervention

⒑ NOA have significantly improved the outcomes of patients with NVAfib, but have no current role in ACS patients.
⒑ NOA are likely to present a better safety profile than VKA in patiens undergoing stent implantation, and RCTs are currently addressing this hypothesis.

⒑ Prasugrel and ticagrelor are the standard of care for high risk ACS patients with no increased risk of bleeding.
⒑ Cangrelor could be a useful treatment for reducing intraprocedural complication pending approval and drug cost.

Best Focus


  • lecture
  • case
read more


  • lecture
  • case
read more

百度联盟: 澳门赌场 澳门赌博网站 澳门博彩 博彩评级 澳门网上赌博 博彩网站 博彩网 澳门葡京赌场 葡京赌场 博彩 百家乐官网 澳门银河官网 时时彩开奖 博狗体育 赌博技巧

百度联盟: 线上百家乐 足球博彩网 博彩评级 澳门百家乐 现金网 ">申博官网 现金博彩 申博开户 澳门博彩 博彩